ASH 2023: Third-generation anti-CD19 CAR T-cells demonstrate efficacy without neurotoxicity in B-cell lymphoma phase 1 clinical trial
The Malaghan Institute of Medical Research announced results of its phase 1 dose escalation trial…
Browsing: ASH
ASH 2023: Combination immunotherapy produces high response rate in early results of trial targeting high-risk follicular lymphoma
Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University…
ASH 2023: Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated
The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate…
ASH 2023: New drug helps narrow racial survival disparity in patients with acute myeloid leukaemia
Non-Hispanic Black patients with acute myeloid leukaemia (AML) are living longer, now that new therapies are available,…
ASH 2023: New personalised therapy improves survival for patients with CLL leukaemia
Personalised treatment for the most common form of adult leukaemia helps patients survive for longer…
ASH 2023: Bispecific antibody drives myeloma precursor condition to undetectable levels in phase II trial
In the first clinical trial of an immunotherapy agent for people with high-risk smouldering myeloma…
ASH 2022: Striving to improve treatment options for acute myeloid leukaemia
If there is one thing a cancer patient wants beyond fast, effective treatment – it…
ASH 2022: Novel drug shows early promise in treating multiple myeloma
A first-of-its-kind drug known as modakafusp alfa has shown early potential in combating multiple myeloma,…
ASH 2022: New data for talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, suggesting durable responses in patients with heavily pretreated multiple myeloma
Results have been announced for the Phase 1/2 MonumenTAL-1 study of talquetamab, an investigational, off-the-shelf…
ASH 2022: Older or high-risk patients with newly diagnosed AML respond well to triplet therapy
Researchers observed encouraging response rates in older or high-risk patients with newly diagnosed acute myeloid…